ReviewActa pharmaceutica Sinica. B2026
Nanobodies targeting SARS-CoV-2 variants.
Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a beta-coronavirus, caused the recent global Coronavirus Disease 2019 (COVID-19) pandemic. Among the virus-encoded proteins, the surface spike (S) protein is critical for viral entry, membrane fusion, and pathogenesis, and its receptor-binding domain (RBD) initiates viral entry by binding to a cellular receptor. This makes the S an important therapeutic target for COVID-19. SARS-CoV-2 mutates frequently, giving rise to five major variants of concern, among which the Omicron variant and its subvariants are less sensitive to current therapeutic antibodies. The first part of this review describes the main protein constituents of SARS-CoV-2 and their functions, the S protein-mediated viral entry and fusion processes, and the main SARS-CoV-2 variants. Nanobodies are single-domain antibodies with high target-binding affinity, strong stability, and low production costs, whose small size facilitates their access to protein regions that are inaccessible to conventional antibodies. Thus, in the second part, we comprehensively review SARS-CoV-2-targeting nanobodies, including those that bind specifically to the RBDs of the S proteins, non-RBD S proteins, and non-S proteins of variants and subvariants of SARS-CoV-2, with the hope that this information will be valuable for the generation of novel SARS-CoV-2-targeting nanobodies with improved potency against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.